Mark E Bensink (Mark Bensink)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Topics

Locally Advanced

Cerebrospinal Fluid

Squamous Cell Carcinoma

Cardiovascular Disease

Top Venues

Current medical research and opinion

Journal of medical economics

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Edgar V Lerma, Kamlesh M Thakker, Mark E Bensink, Richard Lieblich, C Martin Bunke, Wu Gong, Andrew R Rava, Kaijun Wang, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork, Juan Carlos Q Velez
Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database. Kidney360 (2024)
Zheng-Yi Zhou, Mark E Bensink, Nisha C Hazra, Chunyi Xu, Bruce M Hendry, Claire C Sharpe, Mo Zhou
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis. PharmacoEconomics - open (2024)
Juan Carlos Q Velez, Kamlesh M Thakker, Mark E Bensink, Edgar V Lerma, Richard Lieblich, C Martin Bunke, Wu Gong, Kaijun Wang, Andrew R Rava, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork
Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with FSGS in a US Real-World Database. Kidney360 5 (8) (2024)
Edgar V Lerma, Kamlesh M Thakker, Mark E Bensink, Richard Lieblich, C Martin Bunke, Wu Gong, Andrew R Rava, Kaijun Wang, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork, Juan Carlos Q Velez
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy in a Real-World Database. Kidney360 5 (3) (2024)
Juan Carlos Q Velez, Kamlesh M Thakker, Mark E Bensink, Edgar V Lerma, Richard Lieblich, C Martin Bunke, Wu Gong, Kaijun Wang, Andrew R Rava, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork
Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with Focal Segmental Glomerulosclerosis in a U.S. Real-World Database. Kidney360 (2024)
Edgar V Lerma, Kamlesh M Thakker, Mark E Bensink, Richard Lieblich, C Martin Bunke, Wu Gong, Andrew R Rava, Kaijun Wang, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork, Juan Carlos Q Velez
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy in a Real-World Database. Kidney360 5 (3) (2024)
Juan Carlos Q Velez, Kamlesh M Thakker, Mark E Bensink, Edgar V Lerma, Richard Lieblich, C Martin Bunke, Wu Gong, Kaijun Wang, Andrew R Rava, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork
Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with FSGS in a US Real-World Database. Kidney360 5 (8) (2024)
Edgar V Lerma, Kamlesh M Thakker, Mark E Bensink, Richard Lieblich, C Martin Bunke, Wu Gong, Andrew R Rava, Kaijun Wang, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork, Juan Carlos Q Velez
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy in a Real-World Database. Kidney360 5 (3) (2024)
Edgar V Lerma, Kamlesh M Thakker, Mark E Bensink, Richard Lieblich, C Martin Bunke, Wu Gong, Andrew R Rava, Kaijun Wang, Diana T Amari, David Oliveri, Michael V Murphy, David M W Cork, Juan Carlos Q Velez
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy in a Real-World Database. Kidney360 5 (3) (2024)
John Edelsberg, Derek Weycker, Mark E Bensink, Charles Bowers, Gary H Lyman
Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Current medical research and opinion 36 (3) (2019)
Derek Weycker, Ahuva Hanau, Mark Hatfield, Hongsheng Wu, Anjali Sharma, Mark E Bensink, David Chandler, Aaron Grossman, Michael Tarantino
Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. Journal of medical economics 23 (2) (2019)
Derek Weycker, Mark E Bensink, Alexander Lonshteyn, Robin Doroff, David Chandler
Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current medical research and opinion 35 (6) (2019)
Mark E Bensink, Christine Edwards, Charles Bowers, Jon Campbell
Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083-93. Journal of medical economics 21 (6) (2018)
J Mark Stephens, Mark E Bensink, Charles Bowers, Christopher S Hollenbeak
Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population. Current medical research and opinion 35 (2) (2018)
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Tamer Garawin, Mark E Bensink, David Chandler
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. Current medical research and opinion 35 (4) (2018)
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Mark E Bensink, Tamer Garawin, David Chandler
Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. Current medical research and opinion 34 (9) (2018)